Presbyopia Market

Market Overview:

The 7 major presbyopia markets reached a value of USD 1,755.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,513.0 Million by 2035, exhibiting a growth rate (CAGR) of 3.31% during 2025-2035.

The presbyopia market has been comprehensively analyzed in IMARC's new report titled "Presbyopia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Presbyopia is an age-related disorder that affects the ability of the eyes to focus on nearby objects. The ailment develops when the natural lens in the eyes becomes less flexible, making it more difficult for the eye to change focus from distant objects to nearby ones. This results in a decreased ability to read or perform other close-up tasks. Individuals suffering from presbyopia may experience symptoms like blurred vision at normal reading distance, a tendency to hold reading material farther out to make the letters visible, flashes of light, black spots, halos around lights, eyestrain, or headaches following reading or doing close-up work., etc. The diagnosis of this condition requires a combination of underlying indications and medical history. The healthcare professional may perform an eye investigation, such as a refraction assessment and an eye health exam. Additionally, a visual acuity test and slit-lamp examination are recommended to measure vision at distances and assess the structures of the eyes.

The rising incidences of eye disorders, including cataracts and glaucoma, which affect the natural lens of the eye, are primarily driving the presbyopia market. In addition to this, the expanding geriatric population, who are susceptible to alterations in the lens's proteins as well as decreased eye muscles' elasticity, is also augmenting the market growth. Moreover, the widespread adoption of a cholinergic muscarinic receptor agonist eye drop that reduces pupil size by constricting the iris sphincter muscle to enhance near and intermediate visual acuity is creating a positive outlook for the market. Besides this, the escalating utilization of corneal inlay devices, which are implanted at the front of the eye (in the cornea) to help restore close-up vision and increase the depth of focus, is also bolstering the market growth. Additionally, the growing popularity of monovision LASIK surgery, since it permanently changes the shape of the cornea and enhances accurate light focus toward the back of the eye to reduce the need for reading glasses, is acting as another significant growth-inducing factor. Furthermore, the ongoing advancements in intraocular lens implants, which offer a range of treatment options that can provide patients with improved vision and reduced dependence on corrective eyewear, are expected to drive the presbyopia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the presbyopia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for presbyopia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the presbyopia market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the presbyopia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the presbyopia market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current presbyopia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the presbyopia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the presbyopia market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the presbyopia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of presbyopia across the seven major markets?
• What is the number of prevalent cases (2019-2035) of presbyopia by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of presbyopia by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with presbyopia across the seven major markets?
• What is the size of the presbyopia patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of presbyopia?
• What will be the growth rate of patients across the seven major markets?
   

Presbyopia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for presbyopia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the presbyopia market?
• What are the key regulatory events related to the presbyopia market?
• What is the structure of clinical trial landscape by status related to the presbyopia market?
• What is the structure of clinical trial landscape by phase related to the presbyopia market?
• What is the structure of clinical trial landscape by route of administration related to the presbyopia market?